Synthetic biology firm Asimov has launched the LV Edge Producer System, a cell line development service which stabilises gene integration for lentiviral production. The system halves risk of supply chain or product variability, and reduces costs by making GMP plasmid unnecessary. The system reaches E9 TU/mL titer levels in less than six months, and can be carried out on-site at Asimov’s Boston cell line development facility.
How Health Systems Can Prepare to Deploy Platform Engineering
Successful transition to platform engineering involves foundation processes such as continuous integration/delivery, API management, containerization strategies, and Infrastructure as Code (IaC). To implement platform engineering,
